MedicalSutras
Beta-Lactam Antibiotics : Cephalosporins

Beta-Lactam Antibiotics : Cephalosporins

Beta Lactam Antibiotics

Cephalosporins are produced from 7-aminocephalosporanic acid by adding different side chains to the beta-lactam ring or the dihydrothiazine ring.

Cephamycins are similar to cephalosporins but have a methoxy group at position 7 of the beta-lactam ring.

Structure


  • The nucleus is made of 7-aminocephalosporanic acid that consist of a beta-lactam ring and a dihydrothiazine ring fused together.
  • Addition of different side chains at position 7 of the beta-lactam ring alters the antibacterial activity, while modifications at position 3 of the dihydrothiazine ring alter the pharmacokinetic properties.

Mechanism of Action


  • All cephalosporins are bactericidal and inhibits the bacterial cell wall synthesis (similar to penicillin, but binds to different PBPs).

First Generation Cephalosporins


  • Have good activity against gram-positive bacteria and relatively modest activity against gram-negative.

  • Anaerobic cocci (eg. peptostreptococci, peptococci) are sensitive, but not the B. fragilis group.

  • Includes :

    • Cefazolin
    • Cephalexin
    • Cefadroxil
    • Caphalothin
    • Cephapirin
    • Cephradine

Second Generation Cephalosporins


  • Heterogenous group with differences in activity, pharmacokinetics and toxicity.

  • Have broader spectrum than first-generation and are effective against Enterobacter, indole positive Proteus and Klebsiella.

  • Weaker than first generation agents against gram positive bacteria, while are more active against gram-negative organisms.

  • Includes :

    • Cefaclor
    • Cefuroxime
    • Cefprozil
    • Cefamandole
    • Cefonicid
    • Loracarbef
    • Ceforanide
    • Cefuroxime axetil
    • Cephamycins : Cefoxitin, Cefotetan.

Third Generation Cephalosporins


  • Generally less active against gram-positive cocci and anaerobes, but have expanded gram-negative coverage and highly augmented activity against Enterobacteriaceae, including beta-lactamase producing strains.

  • All are resistant to beta-lactamases produced by gram-negative bacteria.

  • Penetrates body fluids and tissues well, and can achieve sufficient levels in CSF to inhibit most susceptible pathogens when given IV.

  • Includes :

    • Cefotaxime
    • Ceftazidime
    • Ceftriaxone
    • Cefixime
    • Cefpodoxime proxetil
    • Cefdinir
    • Cefditoren pivoxil
    • Ceftibuten
    • Cefoperazone
    • Ceftizoxime
    • Moxalactam
    • Ceftamet pivoxil

Fourth Generation Cephalosporins


  • Have extended activity spectrum compared to third generation.
  • Not susceptible to inducible chromosomal beta-lactamases produced by some resistant bacteria.
  • Highly active against Enterobacteriaceae.
  • Includes : Cefepime and Cefpirome.

Fifth Generation Cephalosporins


  • Active against MRSA and some other resistant bacteria.
  • Includes : Ceftaroline fosamil, Ceftobuprole medocaril.

Commonly Used Cephalosporins


Cephalexin


  • Orally used first-generation cephalosporin (widely used in the United States).

  • Excretion is mainly by glomerular filtration and tubular secretion into the urine. Hence, the dosage must be reduced in patients with renal impairment.

  • Indications :

    • Treatment of urinary tract infections
    • Staphylococcal or streptococcal infections, including cellulitis or soft tissue abscess.
  • Dosage : 250-500 mg qid (25-50 mg/kg/d in 4 doses).

Cefazolin


  • Used parenterally.

  • Indications :

    • Surgical prophylaxis.
    • Streptococcal and Staphylococcal infections requiring intravenous therapy.
  • Dosage (IV) : 0.5-2 g every 8 hour (25-100mg/kg/d in 3 or 4 doses), can also be administered intramuscularly.

Cefuroxime


  • Active against some Citrobacter and Enterobacter species, but lacks activity against B. fragilis.
  • Resistant to gram-negative beta-lactamases and effective for treatment of meningitis caused by H. influenzae, N. meningitidis, S. pneumoniae.
  • Concentration in CSF is around 10% of those in plasma.
  • Has been superseded by third generation cephalosporins in the treatment of meningitis.
  • Can be used for single dose IM therapy of gonorrhoea due to PPNG.
  • Cefuroxime axetil : Ester of cefuroxime, 30-50% absorbed orally and then hydrolysed to cefuroxime.

Cefaclor


  • Active against H. inluenzae and Moraxella catarrhalis.
  • Retains significant activity by the oral route but highly susceptible to beta-lactamases.
  • Dosage : 0.25-1.0 g every 8 hour.
  • Loracarbef : similar in activity to cefaclor and more stable against beta-lactamases.

Cefprozil


  • More active against penicillin-sensitive streptococci, E. coli, P. mirabilis, Klebsiella and Citrobacter species.
  • Has good oral absorption (more than 90%).
  • Indications : Bronchitis, ENT and skin infections.
  • Dosage : 240-500mg BD (20mg/kg/day).

Cephamycins


  • Includes Cefoxitin and Cefotetan.
  • Active against anaerobes including B. fragilis strains.
  • Can be used to treat mixed anaerobic infections such as peritonitis, diverticulitis, and pelvic inflammatory disease.

Cefotaxime


  • Highly resistant to many beta-lactamases and has good activity against aerobic gram-negative and some gram-positive bacteria.

  • Poor activity against anaerobes (particularly B. fragilis), S. aureus and Pseudomonas aeruginosa.

  • Attains relatively high CSF levels.

  • Indications :

    • Meningitis caused by gram-negative bacilli.
    • Life-threatening resistant/ hospital-acquired infections.
    • Septicemias.
    • Infections in immunocompromised patients.
    • Alternative to Ceftriaxone for typhoid fever
    • Single dose therapy (1g IM + 1g Probenecid oral) for PPNG urethritis.
  • Dosage (IV) : 1-2g every 6-12 hour (50-200 mg/kg/d in 4-6 doses).

Ceftazidime


  • Highly active against Pseudomonas aeruginosa.
  • Indications : Febrile neutropenic patients with hematological malignancies, burn, etc.
  • Dosage : 1-2g every 8-12 hourly IM or IV (75-150 mg/kg/d in 3 doses).
  • Adverse Effects : Neutropenia, Thrombocytopenia, Rise in plasma transaminase and blood urea.

Ceftriaxone


  • Have a half-life of around 8 hours, hence, longer duration of action and once or twice daily dose is effective.

  • Have high efficacy against wide range of serious infections, eg. bacterial meningitis (esp. in children), multi-resistant typhoid fever, complicated urinary tract infections, abdominal sepsis and septicaemia.

  • Indications :

    • Skin, soft tissue or urinary infections : 1-2 g IV or IM per day.
    • Meningitis : 4 g followed by 2 g IV (75-100mg/kg) once daily for 7-10 days.
    • Gonorrhoea (incl. PPNG) and Chancroid : 1g IM single dose is curative.
    • Typhoid : 4g IV daily x 2 days, followed by 2g/day (75mg/kg) till 2 days after fever subsides.
    • Alternative drug for syphilis : 1g IM for 7 days (early syphilis) and for 15 days (late syphilis).
  • Adverse Effects : Hypoprothrombinaemia and bleeding.

  • Combination (to overcome resistance) :

    • Ceftriaxone (250mg) + Sulbactam (125mg).
    • Ceftriaxine (1g) + Tazobactam (125mg).

Cefixime


  • Orally active third generation cephalosporin.
  • Highly active against Enterobacteriaceae, H. influenzae, Streptococcus pyogens.
  • Resistant to many beta-lactamases.
  • Not active against S. aureus, most pneumococci and Pseudomonas.
  • Half-life is around 3 hours.
  • Indications : Respiratory, urinary and biliary infections.
  • Dosage : 200mg twice daily or 400mg once daily.
  • Adverse Effects : Stool changes and diarrhoea.
  • *Due to increasing resistance, cefixime is no longer recommended for the treatment of uncomplicated gonococcal urethritis and cervicitis.

Cefipime


  • Relatively resistant to chromosomally encoded and some extended spectrum beta-lactamases.
  • Active against many Enterobacteriaceae that are resistant to other cephalosporins, but inactive against MRSA.
  • Indication :Sserious infections like hospital-acquired pneumonia, febrile neutropenia, bacteraemia and septicaemia.
  • Dosage : 0.5-2 g every 12 hour IV (75-120mg/kg/d in 2 or 3 divided doses).

Ceftaroline fosamil


  • Pro-drug, that after IV infusion is rapidly converted to active metabolite, ceftaroline.

  • Has increased affinity to PBP 2a, which mediates methicillin resistant in staphylococcus and PBP2b and PBP2x (in penicillin resistant Streptococcus pneumoniae).

  • Not active against AmpC or extended spectrum beta-lactamase producing organisms.

  • Indications :

    • Complicated skin and soft tissue infections.
    • Community-acquired pneumonia particularly those caused by MRSA and penicillin resistant Streptococcus pneumoniae.
  • Dosage : 600mg IV every 12 hours.

Points to Note


  • Several cephalosporins (eg. cefotaxime, ceftriaxone and cefepime) penetrate into CSF in sufficient concentration and hence, useful in the treatment of meningitis.
  • Cephalosporins also cross the placenta and are found in high concentrations in synovial and pericardial fluids.
  • Concentrations sufficient for treatment of ocular infections (caused by gram positive and certain gram negative bacterias) can be achieved by systemic administration of third generation cephalosporins.
  • Second generation cephalosporins may exhibit in-vitro activity against Enterobacter species, but resistant mutants that express a chromosomal beta-lactamase that hydrolyses these compounds are readily selected. Hence, these drugs should not be used to treat Enterobacter infections.

References


  • Essentials of Medical Pharmacology 8th Edition (K.D. Tripathi)-Jaypee Brothers Medical Publishers (P) Ltd.
  • James Ritter, Rod Flower, Graeme Henderson, Yoon Kong Loke, David MacEwan, Humphrey Rang - Rang & Dale’s Pharmacology-Elsevier (2019).
  • Laurence L. Brunton - Goodman & Gilman's Manual of Pharmacology and Therapeutics-McGraw-Hill Medical (2008).
  • Basic and Clinical Pharmacology, 15th Edition, Bertram G. Katzung, Todd W. Vanderah, McGraw Hill.

*This article is an excerpt from the above mentioned books and Medical Sutras does not make any ownership or affiliation claims.